ClinicalTrials.gg
CompletedNCT06704971Updated Nov 16, 2026

Assessing Cognitive Decline at Home

An observational study in Mild Cognitive Impairment, Mild Dementia and Dementia Alzheimers, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Stanford University · Observational

How we know

Updated Nov 16, 2026Now CompletedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
22
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Cognitive Dysfunction by Stanford University — 3 open to participants now, 7 under way, none of them phase 3. Cognitive Dysfunction · Stanford University.

Started
2024
with 4 others
Observational
8 of 14
1 open now
Registered
13th of 14
by date

Among the 14 studies in Cognitive Dysfunction by Stanford University, this one is one of 5 that started in 2024, is one of 8 observational ones, and was the 13th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

3 of the 14 studies in Cognitive Dysfunction by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Cognitive Dysfunction by Stanford University, or all of them as a file.
02

Study summary

Neuropsychiatric symptoms (NPS) refer to a range of mental and emotional issues that can be observed through how patients move, perform daily tasks, and express feelings on their faces. In this study, the investigators want to find ways to accurately and unobtrusively track these symptoms in people's homes over time. Our goals are to note when these symptoms happen, predict potential problems, and gather clear data to help doctors make accurate diagnoses.

To do this, the investigators will first collect information from participants who have in-home sensors. the investigators will then use special computer programs that can recognize everyday activities and identify features that connect to scores from the Mild Behavioral Impairment Checklist (MBI-C). These scores will be compared to a questionnaire (NPIQ) filled out by caregivers or family members, along with any relevant information from doctors about the patients' symptoms. The investigators aim to see how these features can help differentiate between types of NPS, such as mood changes and agitation.

Finally, the investigators will create a dashboard for doctors that summarizes the patterns of these symptoms in patients, making it easier to monitor and manage their mental health.

Read the detailed description

What the investigators would need from participants:

  • Collect the participants' own data of daily activities from a room in participants home such as the participant's living room via a small camera the investigators provide for no less than 7 days and up to 30 days. The participant will have full control over the camera to turn on and off.
  • The participant and a loved one will regularly answer short surveys asking about the participant's mood and daily functioning.
  • At the end of agreed observation period, return the memory card of the participant's collected data from the camera in person or pre-paid FedEx envelope.
03

Conditions studied

  • Mild Cognitive Impairment
  • Mild Dementia
  • Dementia Alzheimers
  • Dementia
  • Memory Impairment
  • NPS
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Older Adults - 65+

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65+ years old
  • Any age and ethnicity.
  • With or without, or at risk of mild to moderate dementia and healthy controls.
  • Availability of a study partner (informant) who has contact with the patient at least once a week (this can also be the surrogate/LAR but does not necessarily have to be)

Exclusion criteria

Exclusion criteria:

  • Those with severe mobility impairments
  • participants in non-home settings (skilled nursing facilities, etc.).
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
22 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. develop a personalized and clinically interpretable NPS assessment system

    Assessing NPS relies primarily on clinician observation \& interviews with caregivers, usually within brief \& infrequent clinical visits. Precise assessment and monitoring methods would incorporate objective, patient- \& caregiver-friendly, real-time tools and provide reliable \& frequently captured data. We aim to create a system that can monitoring individual and subsyndromes of NPS; and detect early changes in NPS by automatically quantifying \& detecting relevant behavioral abnormalities based on both intra- \& inter-individual comparisons. Our approach is a video sensor, information processing, \& alert system that utilizes in-home cameras \& ambient sensors with video features that can recognize \& track behaviors securely, pre-defines domains involved in a behavior; personalizes the results by assessing the individual's behavioral norms and the home environment; and analyzes, learns, and provides explainable items from different modalities of data: time, location, video, and audio.

    Time frame: 2 year

  2. NPS Clinical Dashboard

    Overall, the investigators envision the clinical dashboard as a transformative tool that delivers clear and comprehensive data on each individual. Therefore enhancing the quality of diagnosis of NPS for individuals, leading to better patient interventions and more effective long term management strategies.

    Time frame: 1 year

Secondary outcomes

  1. generate Data and support for a large-scale study or clinical trial within the context of an R01.

    the ultimate goal of this project is to generate feasibility data and infrastructure for a large-scale study with a possible clinical trial within the context of an R01. In parallel, to translate the technology into clinical practice, we will work with the Stanford Office of Technology Licensing (OTL) to productize the outcomes.

    Time frame: 2 years

07

Study locations

1 site
  • Clinical Excellence Research Center
    Palo Alto, California 94304, United States
08

References and documents

Publications

  • Gould CE, Davis CH, Schuz N, Lin FV, Samus QM, Terada T, Daniel M, Tee S, Adeli E. Designing AI-Enabled Video Monitoring Clinician Dashboard for Neuropsychiatric Symptoms: A Survey of User Needs. Am J Geriatr Psychiatry Open Sci Educ Pract. 2026 Mar;9:46-51. doi: 10.1016/j.osep.2026.01.001. Epub 2026 Feb 8. PubMed 41987876 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Oct 2025, 12 months.

Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's 12 months is below that.

Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2025, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 26, 2024
StartActual
Oct 1, 2024
Primary completionActual
Oct 8, 2025
CompletionActual
Dec 8, 2025was Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Primary completion
Oct 30, 2025→Oct 8, 2025
Nov 16, 2026
Study completion
Dec 30, 2026→Dec 8, 2025 (actual)
Nov 16, 2026
Enrollment
25 (estimated)→22 (actual)
Nov 16, 2026
Documents
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Primary completion Oct 30, 2025→Oct 8, 2025
    Study completion Dec 30, 2026→Dec 8, 2025 (now actual)
    Enrollment 25 (estimated)→22 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06704971
Responsible party
Ehsan Adeli (Asst. Professor, Stanford University) — Principal investigator
First posted
Nov 26, 2024
Start date
Oct 1, 2024
Primary completion
Oct 8, 2025
Completion
Dec 8, 2025
Last update
Nov 16, 2026

Study contacts

Ehsan Adeli, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion